⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8923194 | 0.85 | — | — | |
| SCHEMBL12364140 | 0.79 | — | — | |
| SCHEMBL16621751 | 0.79 | — | — | |
| SCHEMBL12364141 | 0.79 | — | — | |
| SCHEMBL24872020 | 0.77 | IDO1 (0.32) | — | |
| SCHEMBL13290983 | 0.77 | — | — | |
| SCHEMBL13882103 | 0.77 | — | — | |
| SCHEMBL16303103 | 0.76 | — | — | |
| SCHEMBL16621750 | 0.75 | — | — | |
| SCHEMBL14572129 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230337517-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-10-19 | — | — | US | disclosed |
| US-10011573-B2 | Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-07-03 | — | — | US | disclosed |
| US-9963445-B2 | Chemical compounds | SYNGENTA LIMITED (GB) | 2018-05-08 | — | — | US | disclosed |
| US-20180037571-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180010132-A1 | INHIBITION OF PRMT5 TO TREAT MTAP-DEFICIENCY-RELATED DISEASES | NOVARTIS AG (CH) | 2018-01-11 | — | — | US | disclosed |
| US-9822097-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170283807-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2017-10-05 | — | — | US | disclosed |
| US-20170183319-A1 | HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-06-29 | — | — | US | disclosed |
| US-9676749-B2 | Compositions and methods for cancer detection and treatment | OHIO STATE INNOVATION FOUNDATION (US) | 2017-06-13 | — | — | US | disclosed |
| US-9611248-B2 | Chemical compounds | SYNGENTA LIMITED (GB) | 2017-04-04 | — | — | US | disclosed |
| US-8143412-B2 | Inhibitors of proliferation and activation of signal transducer and activator of transcription (STATs) | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2012-03-27 | — | — | US | disclosed |
| US-8119827-B2 | Compounds for treatment of cell proliferative diseases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110053992-A1 | Novel Inhibitors of Proliferation and Activation of Signal Transducer and Activator of Transcription (STATS) | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2011-03-03 | — | — | US | disclosed |
| US-20110021805-A1 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-01-27 | — | — | US | disclosed |
| US-7745468-B2 | tyrphostin-like compounds that display a significant potency as kinase inhibitors, cause the downregulation of c-myc proto-oncogene and inhibit the growth and survival of cancerous cell lines; antiproliferative agents | Board of Regents, University of Texas Systems The (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100152143-A1 | Methods of Treating Skin Disorders with Caffeic Acid Analogs | MOLECULIN, LLC (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | XIANG JASON SHAOYUN | 2010-02-04 | — | — | US | disclosed |
| US-7632838-B2 | 11-beta HSD1 inhibitors | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| US-20070232668-A1 | Orally Bioavailable Caffeic Acid Related Anticancer Drugs | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2007-10-04 | — | — | US | disclosed |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | WYETH (US) | 2007-09-20 | — | — | US | disclosed |